Paid Clinical Trials Gulfport
Discover 22 paid clinical trials in Gulfport, Mississippi. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Epcoritamab & LenalidomideA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor:
Genmab
Location:
Code:
NCT06508658
Conditions
Diffuse Large B-Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Epcoritamab
Rituximab
Lenalidomide
Oxaliplatin
Gemcitabine
Immune Checkpoint InhibitorsAn Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Sponsor:
University of Rochester NCORP Research Base
Location:
Code:
NCT05364086
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
OrforglipronA Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06672939
Conditions
Obesity
Overweight
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Orforglipron
Placebo
BI 1839100A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Sponsor:
Boehringer Ingelheim
Location:
Code:
NCT06360094
Conditions
Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BI 1839100
Placebo
Investigational CMV Vaccine Study for Volunteers Ages 9–15A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
Sponsor:
Moderna
Location:
Code:
NCT05575492
Conditions
Cytomegalovirus
Eligibility Criteria
Sex: All
Age: 9 - 25
Healthy Volunteers: Accepted
Interventions
mRNA-1647
Placebo
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Targeted TherapyTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05564377
Conditions
Advanced Malignant Solid Neoplasm
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Locally Advanced Malignant Solid Neoplasm
Malignant Female Reproductive System Neoplasm
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Alpelisib
Binimetinib
Biopsy Procedure
Biospecimen Collection
Bone Marrow Aspiration
AZD5004Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Sponsor:
AstraZeneca
Location:
Code:
NCT06579105
Conditions
Diabetes Mellitus, Type 2
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo (placebo matching AZD5004 film-coated tablet)
AZD5004
Semaglutide
Immunotherapy with SurgeryComparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04510597
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Cytoreductive Nephrectomy
Active Comparator
PirtobrutinibA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor:
Loxo Oncology, Inc.
Location:
Code:
NCT06588478
Conditions
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pirtobrutinib
Enlicitide DecanoateEnlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06008756
Conditions
Arteriosclerosis
Hypercholesterolaemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Enlicitide Decanoate
Placebo